Epigenetic Therapy in Breast Cancer

Cancer progression can be controlled by both genetic and epigenetic alterations. Only epigenetic alterations are reversible unlike the genetic alterations. This can be a important advantage to suggest that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. The US Food and Drug Administration approved some DNA methylation inhibitors and histone deacetylation inhibitors as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer